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Abstract
Colorectal cancer (CRC) is the third most commonly 
diagnosed cancer in the world. The incidence and 
mortality show wide geographical variations. Screening 
is recommended to reduce both incidence and 
mortality. However, there are significant differences 
among studies in implementation strategies and 
detection. This review aimed to present the results 
and strategies of different screening programs 
worldwide. We reviewed the literature on national and 
international screening programs published in PubMed, 
on web pages, and in clinical guidelines. CRC Screening 
programs are currently underway in most European 
countries, Canada, specific regions in North and South 
America, Asia, and Oceania. The most extensive 
screening strategies were based on fecal occult blood 
testing, and more recently, the fecal immunochemical 
test (FIT). Participation in screening has varied greatly 
among different programs. The Netherlands showed 
the highest participation rate (68.2%) and some areas 
of Canada showed the lowest (16%). Participation rates 
were highest among women and in programs that used 
the FIT test. Men exhibited the greatest number of 
positive results. The FIT test has been the most widely 
used screening program worldwide. The advent of this 
test has increased participation rates and the detection 
of positive results. 
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Core tip: Colorectal cancer is the third most commonly 
diagnosed cancer worldwide. The incidence and 
mortality show wide geographical variations across 
the world. Screening is recommended to reduce both, 
however, there are significant differences among 
studies in implementation strategies and detection. 
This review aimed to present the results and strategies 
of different screening programs worldwide.
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INTRODUCTION
Colorectal cancer (CRC) is one the most commonly 
diagnosed cancers worldwide. Among men with cancer, 
CRC ranked third in prevalence (746000 cases, 10% 
of the total male population), after lung and prostate 
cancers. Among women with cancer, CRC ranked 
second in prevalence (614000 cases, 9.2% of the total 
female population), after breast cancer. CRC incidence 
and mortality show wide geographical variations 
across the world. When comparing age-standardized 
incidence rates (ASRis) of CRC in different countries, 
we found the highest rates in Australia and New 
Zealand, and the lowest rates in Western Africa[1]. 
Nearly 55% of CRC cases occur in developed 
regions, but CRC-related mortality is highest in less 
developed countries (including regions of Africa). This 
poor survival is probably due to the lack of available 
health resources. However, high- and low-income 
countries also show large variations in the proportion 
of the population included in CRC registries. These 
variations may arise from underdiagnoses, due to local 
medical and economic situations[2]. 
In many regions, the risk of developing CRC is 
around 5%, and of those patients, 45% will die despite 
treatment[3]. According to GLOBOCAN data, 694000 
individuals died in 2012 from CRC worldwide (374000 
men and 320000 women). Mortality rates show less 
variability than incidence rates; the highest estimated 
CRC-related mortality rates in both sexes were found 
in Central and Eastern Europe, and the lowest were 
found in Western Africa[1].
In Europe, there are huge variations in the ASRis of 
CRC; the lowest incidences were observed among men 
and women in Bosnia Herzegovina (30 per 100000 
and 19 per 100000, respectively) and in Albania 
(13 and 11 per 100000 respectively). Among men, 
the highest incidences were observed in Slovakia, 
Hungary, and the Czech Republic. Among women, the 
highest incidences were found in Norway, Denmark, 
and Holland[1]. Although mortality rates are generally 
geographically similar to incidence rates, mortality 
is sometimes high in countries with relatively low 
incidence rates (Moldavia, Russia, Montenegro, Poland, 
and Lithuania)[4]. In North America, the ASRi of CRC 
was estimated to be 26.1 per 100000. In 2016, the 
American Cancer Society estimated that 134490 new 
CRC cases would be diagnosed in individuals of both 
sexes, and that 49190 individuals would die from CRC 
in the United States[5]. In the Eastern Mediterranean 
region, the highest CRC incidence was found in Israel 
(36 per 100000), followed by Jordan and Kazakhstan 
(26 and 23 per 100000, respectively). The highest 
mortality rates were found in Jordan, followed by 
Kazakhstan, Armenia, and Israel. In the Asian Pacific 
region, the incidence of CRC varies among regions. 
The highest incidence was reported in South Korea 
(ASRi: 45 per 100000). Singapore and Japan also had 
high incidence rates (ASRis: 34 and 32 per 100000, 
respectively). Compared to those regions, other 
countries, like India, have much lower ASRis (6 per 
100000) and age-standardized mortality rates (ASRm: 
5 per 100000)[4]. 
CRC qualifies for screening according to the criteria 
established by Wilson and Jungner as the “gold 
standard of screening assessment”[6-8]. The criteria 
that CRC fulfills include its high incidence rate, its 
long preclinical phase, its recognizable and tractable 
precursor, and the correlation between the tumor 
stage and mortality rate. Although the value of the 
Wilson and Jungner criteria remains undisputed to this 
day, newer policy tools are now available (Table 1)[9]. 
Screening for CRC appears to be cost-effective 
compared to no screening[10]. However, CRC screening 
programs must be adapted to the risk of each 
population. An average-risk population is defined as a 
population of individuals aged 50 years or older, with 
no additional risk factors. The recommended screening 
for the average-risk population is one of the following: 
an annual or biennial fecal immunochemical test 
(FIT); sigmoidoscopy every 5 years; or colonoscopy 
every 10 years. When subgroups are identified and 
characterized with a higher-than-average incidence 
of colorectal neoplasia, it is necessary to increase 
the screening frequency to achieve program cost-
effectiveness[11]. Despite recommendations, screening 
is currently offered to only a small proportion of the 
population.
In this review, we evaluated the results of 17 
screening programs. We obtained ASRis and ASRms 
in the different countries reviewed from the website: 
www.globocan.iarc.fr. A literature search was con-
ducted in PUBMED with the following keywords: 
Screening, Colorectal Cancer, Bowel cancer, guidelines, 
programmes, program, results, FIT, guaiac, first 
round, pilot, rounds, Europe/ United Kingdom/ 
Ireland/ The Netherlands/ Lithuania/ Italy/ Croatia/ 
Czech Republic/ Slovenia/ France/ Canada/ California/ 
USA/ Korea/ Australia/ Thailandia/ Taiwan/ Chile. CRC 
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screening program characteristics were also collected 
from national governmental websites. To evaluate and 
compare screening programs, we used universally 
applicable CRC screening indicators. 
CRC SCREENING TESTS
Stool tests
It has been established that CRC mortality could be 
reduced by screening with periodic fecal occult blood 
tests (FOBTs), followed by colonoscopy when the 
results were positive. A systematic review published 
in 2008, which included 4 clinical controlled trials 
involving over 300000 participants, found that 
screening with FOBT reduced the relative risk (RR) of 
CRC mortality by 16%, without adjustment, and by 
25% after adjusting for screening attendance[12]. The 
follow-up of those patients showed that the effect of 
screening was reduced CRC-mortality, and this effect 
persisted for over 30 years[13]. A reduction in the RR of 
CRC incidence was also detected in follow-up, mainly 
due to the removal of adenomatous polyps. This effect 
was greater among individuals that received annual 
screenings (20% RR) than among those that received 
biennial (17%) screenings[14].
Currently, there are two different tests available: 
the FIT and the guaiac fecal occult blood test (G-FOBT). 
The FIT achieved significantly higher detection rates 
for advanced adenomas and CRC than the G-FOBT. 
Although the FIT was more sensitive than the G-FOBT 
(61% vs 23.8%, respectively), its specificity was 
slightly lower (95.1% vs 97.7%, respectively)[15,16]. 
Participation rates appeared to be higher in screening 
programs that used FIT compared to those that used 
G-FOBT[15]. This issue is probably related to the facts 
that FIT does not require dietary restrictions (due 
to its specificity to human hemoglobin [Hb]) and 
that only one sample is needed in most screening 
programs[16]. Additionally, FIT offers quantitative 
results (ng Hb per mL buffer or µg Hb per gram 
feces) and an automated reading of the results. 
The cut-off value for the amount of Hb detected can 
be predetermined by the investigator. Several cut-
off values have been used with different sensitivity 
and specificity rates. The investigator can adjust the 
cut-off value to limit the number of colonoscopies 
required, and thus, avoid overextending the available 
endoscopic resources. An optimum cut-off value has 
not been established; therefore, the choice should 
be based on the availability of endoscopic resources, 
the epidemiology of CRC in the study population, and 
the expected participation in the program[17]. Values 
between 20 and 30 µg/g are recommended when the 
Health Care System can accommodate colonoscopies 
for approximately 5% (expected FIT positivity rate) of 
the population study (aged 50-74 years)[18]. 
Based on current evidence, the FIT has been 
recommended as the first option for detecting fecal 
occult blood in CRC screening[19]. Most European 
countries with an organized screening program are 
currently using the FIT. This test has replaced the 
G-FOBT in screening programs in the United Kingdom 
since 2014 and in France since 2015[4].
Other non-invasive techniques are available, 
such as the fecal DNA analysis. These tests identify 
molecular alterations in adenomas and CRC cells. 
However, these tests are currently underused, due to 
the high cost and relatively low cost-effectiveness[20].
Invasive techniques
Flexible sigmoidoscopy screening was shown to be 
effective in reducing the incidence and mortality 
rates of CRC[21,22]. It should be taken into account 
that, when a distal adenomatous polyp is detected in 
a sigmoidoscopy, a colonoscopy is required. This is 
necessary, because the characteristics of adenomas 
found in the rectum and sigma are correlated with the 
probability of presenting a proximal CRC[23,24].
Colonoscopy screening is used in several programs. 
Data are scarce from randomized clinical trials that 
have attested to its effectiveness. However, several 
observational studies have reported that colonoscopy 
screening reduced CRC mortality and incidence, mainly 
due to its great capacity for detecting neoplasias 
and adenomas. In a case-control study, performing 
a colonoscopy, regardless of its indication, was 
associated with a large reduction in the risk of CRC 
in the following 10 years after the test. This effect 
was greater when the colonoscopy had been used 
as a screening test[25]. Several cohort studies have 
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Table 1  New screening criteria (Adapted from: Andermann et al [9]
Emerging screening criteria proposed after Wilson and Junger principles
The screening programme should respond to a recognized need
The objectives of screening should be defined at the outset
There should be a defined target population
There should be scientific evidence of screening programme effectiveness
The programme should integrate education, testing, clinical services and programme management
There should be quality assurance, with mechanisms to minimize potential risks of screening
The programme should ensure informed choice, confidentiality and respect for autonomy
The programme should promote equity and access to screening for the entire target population
Programme evaluation should be planned from the outset
The overall benefits of screening should outweigh the harm
Navarro M et al . CRC population screening programs worldwide
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ages 50 and 69 years, and randomly assigned them 
to undergo either a one-time colonoscopy or the 
biennial FIT. After the first round of FIT screening, 
they confirmed a similar CRC detection rate with 
both methods. However, advanced adenomas and 
other adenomas were detected at a higher rate 
in the colonoscopy than in the FIT groups. This 
result confirmed, once again, the superiority of the 
colonoscopy for detecting this type of lesion. Therefore, 
the colonoscopy has higher potential than the FIT for 
reducing the CRC incidence. Nevertheless, the higher 
participation rate in the FIT group (34.2% vs 24.6%), 
and the biennial periodicity of this test may reduce 
the apparent advantage of colonoscopy over the long 
term[32]. Final results from that study are expected in 
the next few years.
CRC SCREENING PROGRAMS
CRC screening programs in Europe
In 2003, based on compelling evidence, the Council 
of the European Union recommended that all Member 
States should establish early detection programs 
with CRC screening for men and women aged 50 
to 74 years, with annual or biennial FOBTs, followed 
by colonoscopy, when the results were positive[33]. 
Following this recommendation, several CRC screening 
programs were launched in Europe, with wide variations 
in screening practices, probably due to different 
preexisting screening programs (pilots, opportunity-
based, or organized) in several countries. Variations 
among different countries also arose due to differences 
in financial resources available for research and 
differences in colonoscopy capacities.
In 2015, 24 countries in the European Union had 
established or were preparing to organize country-
wide CRC screening programs. For example, Finland, 
France, Slovenia, and the United Kingdom had 
completely implemented organized programs. In 
Belgium, the Netherlands, Denmark, Ireland, Italy, 
Malta, Poland, and Spain, programs were being 
launched. Norway, Portugal, and Sweden were in the 
pilot phase. In contrast, other countries, including 
Slovakia, with the highest CRC rate in Europe[1], did 
not have a national screening program. Similarly, 
no screening programs existed in Bulgaria, Albania, 
Bosnia, Herzegovina, Kosovo, Macedonia, Montenegro, 
Romania, Serbia, and Russia[4].
An analysis of different programs in several 
European countries showed that Croatia and the 
Czech Republic had the lowest participation rates 
(< 25%), and both countries reported high ASRms 
(18.7% and 15.4%, respectively), followed by France 
(participation rate 34.3%). The other countries 
achieved better participation rates (over 45%); the 
highest participation was observed in the Netherlands, 
followed by Slovenia. The Netherlands had the highest 
positive test rate (test positivity, 12.2%), but the 
lowest cut-off value for the FIT test: 15 µg/g. The 
confirmed this finding. One study showed that, in an 
average-risk population, performing a colonoscopy was 
associated with a 67% reduction in CRC incidence after 
an 8-year follow-up[26]. Another study demonstrated 
the long-term protective effect of a polypectomy. When 
a colonoscopy was performed with a polypectomy of 
at least one adenoma > 5 mm, the CRC incidence was 
reduced by 80% after a 10-year follow-up[27].
Colonoscopy quality has varied in reports from 
different endoscopists. For this reason, over the 
last decade, a series of quality indicators for colono-
scopy have been described. However, application of 
these indicators has not become well established in 
endoscopic practice[28]. Currently, the main quality 
indicator among endoscopists is the adenoma detection 
rate (ADR). The ADR is defined as the proportion of 
screening colonoscopies performed by a physician that 
detected at least one histologically confirmed colorectal 
adenoma or adenocarcinoma. The recommended ADR 
is ≥ 25% (men ≥ 30%, women ≥ 20%)[29]. Several 
studies have demonstrated a strong correlation 
between the ADR record of an endoscopist and the 
probability of diagnosing CRC within a given number of 
months of a colonoscopy (an interval CRC) [24]. Despite 
the clinical importance of this measure, large variations 
remain among endoscopists.
One study analyzed the results of colonoscopies 
performed in the US through an integrated health 
services organization, over a 12-year period. The 
association between the ADR and the risk of diag-
nosing CRC within 6 mo to 10 years after the first 
colonoscopy was evaluated, and the risk of death from 
cancer was calculated. They studied a total of 314872 
colonoscopies performed by 136 gastroenterologists, 
with ADRs that ranged from 7.4% to 52.5%. They 
identified 712 interval colorectal adenocarcinomas and 
147 associated deaths. The gastroenterologists were 
placed into quintiles, based on their ADRs (lowest 
ADR quintile ≤ 19.06% and highest ADR quintile 
≥ 33.51%). They found that patients examined by 
gastroenterologists in the lowest ADR quintile had 
almost double the risk of being diagnosed with an 
interval cancer compared to patients examined by 
gastroenterologists in the highest quintile. In addition, 
the risk of a fatal interval cancer was reduced by 62% 
among patients examined by gastroenterologists in 
the highest quintile. Each 1% increase in the ADR was 
associated with a 5% decrease in the risk of a fatal 
interval colorectal cancer[30].
Although the colonoscopy is more effective than 
the FOBT for detecting neoplasias and adenomas, 
the FOBT is more readily accepted by participants in 
population screening programs. Thus, the higher FOBT 
participation rates may counteract its lower detection 
capacity[31]. The COLONPREV study hypothesized that 
biennial FIT screening would be non-inferior to a one-
time colonoscopy, for reducing CRC-related mortality 
among subjects with average risk. They recruited 
more than 50000 asymptomatic participants between 
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second highest test positivity was found in Ireland (10% 
test positivity, with a cut-off value 20 µg/g). In Italy, 
with the same cut-off value, test positivity was 5.8%, 
and in Slovenia, it was 5.9%. The lowest test positivity 
rates were found in England and France (2% and 2.8%, 
respectively), where the G-FOBT was used. In Croatia, 
Lithuania, and the Netherlands, the proportion of 
colonoscopies performed did not exceed 75%; but in 
the Czech Republic and Slovenia, the proportions were 
above 95%. In England, a very high CRC percentage 
was detected (10.1% of patients a with positive G-FOBT 
result), but only 2% of all patients had a positive 
G-FOBT. Ireland had a similar CRC percentage (9%), 
but also a greater number of patients had positive FIT 
results (10%). The highest detection rate was found 
in the Netherlands (5.9 per 1000 screenings), followed 
by Ireland (3.3 per 1000 screenings). More detailed 
results are described below and in Table 2.
Spain: Different screening programs have been 
implemented in all areas of Spain for the population 
aged 50-69 years. These programs mostly use the FIT. 
In 2014, participation rates varied among the regions, 
but the average was 49.2%. More women than men 
participated (51.41% vs 47.01%). On average, 6.56% 
of test results were positive, with a higher percentage 
found in men (8.2%) than in women (5.17%). 
The positive predictive value (PPV) for cancer was 
4.70%. The CRC detection rate was 2.75 per 1000 
screenings[34].
The Netherlands: In 2011, the Netherlands decided 
to implement a national population screening program 
for CRC. The program began in 2014, with the FIT 
test and a cut-off value of 15 µg/g. This program 
achieved a 68.2% participation rate. Initially, it was 
necessary to increase the cut-off value (from 15 µg/g 
to 47 µg/g ), because the proportion of individuals with 
positive tests was higher than expected (12%). This 
proportion exceeded the number of false positives, and 
it surpassed the capacity to perform colonoscopies. 
With the first cut-off value, test positivity was 10.1% 
in women and 14.5% in men. Colonoscopies were 
performed in 74.3% of these patients; among these, 
CRC was detected in 763 (6.7%) and advanced 
adenoma was detected in 33.5%. The CRC detection 
rate was 5.9 per 1000 inhabitants and the PPV was 
6.7%[35].
Ireland: The first pilot program in Ireland was the 
Adelaide and Meath Hospital/Trinity College Dublin 
Colorectal Cancer Screening Program (TTC-CRC-SP). 
It included a population aged 50 to 74 years, and it 
applied the FIT (OC Sensor, cut-off value 20 µg/g). 
The participation rate was 51% (58% women and 
42% men). The proportion of individuals with positive 
test results was 10%. Of the colonoscopies performed 
(87%), advanced adenomas were detected in 99 
patients (24%) and CRC was detected in 38 (9%). 
The PPVs for CRC and advanced adenoma were 4% 
and 5%, respectively, and the CRC detection rate 
was 0.33%[36]. A second round was conducted, where 
they excluded patients that had changed residence, 
had been diagnosed with cancer, and had died. The 
participation rate was 48%, and 375 patients had 
positive test results (8%). Of the patients with a 
Table 2  Results of European Screening Programs
Country Netherlands Italy Ireland Lithuania Croatia Czech 
Republic
Slovenia England France
ASRi 40.2 33.9 34.9 23.4 32.9 39.9 37 30.2 36.1
ASRm 13.4 10.8 12.2 13.7 18.7 15.4 16.2 10.7 12.9
Period 2014-2015 2007-2009 2008-2009 2009-2012 2007-2011 2000-2011 2009-2014 2006-2010 2008-2009
Age 55-75 50-69 50-74 50-74 50-74 > 50 50-69 60-69 50-74
Test FIT FIT FIT FIT gFOBT gFOBT/FIT FIT gFOBT gFOBT
Participation, 
n (%)
129395 (68.2) 81619 (54.4) 9993 (51) 271396 (46) 210239 (19.9) 521429 (22.7) 152475 (60.43) 1079293 (52) 2964976 (34.3)
M, n (%) 2126 (42) 55.23% 510864 (49.6) 32.10%
F , n (%) 2937 (42) 65.53% 568429 (54.4) 36.20%
Positive test, 
n (%)
15802 (12.2) (5.8) 514 (10) 19455 (7.2) 12477 (6.9) 31794 (6.1) 8108 (5.9) 21106 (2%) 82786 (2.8)
M, n (%) 14.50% 254 (5) 7.60% 12776 (2.5) 3.30%
F, n (%) 10.10% 260 (5) 4.70% 8330 (1.5) 2.40%
Colonoscopies 
performed 
74.30% 92.50% 87% 66.10% 66% 95.70% 98.90% 83% 88.40%
Advanced 
adenomas, n (%)
3832 (33.5) 702 99 (24) 3.90% 41% 3077 1887 (25.16) 1721 (9.8) 14276
PPV Advanced 
adenomas 
NA 30.20% 5% NA NA 16.80% NA NA 19.60%
CRC, n (%) 763 (6.7) 70 38 (9) 3.10% 472 (3.6) 829 159 (2.16) 1772 (10.1) 7.50%
PPV CRC 6.70% 3% 4% NA NA 4.50% NA NA NA
CRC detection 
rate per 1000
5.9 1.6 3.3 0.2 NA 1 NA NA 1.9
NA: Not available.
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positive test, 87% underwent a colonoscopy. The PPV 
for CRC was similar to that of the first round (4%), 
and the CRC detection rate was 0.12%[37].
Italy: Lombardy is a densely populated northern 
region of Italy with the highest incidence of CRC. The 
screening program began with the population aged 
50-69 years, in 2005-2006. They applied the FIT with 
a cut-off value of 20 µg/g. The second round of the 
program had been completed in 2009. The PPVs for 
advanced adenoma were 29% in the first round, and 
30.2% in the second round. The PPVs for CRC were 4% 
and 3%, respectively. The PPVs for advanced adenoma 
and CRC were higher in people aged 60-69 years 
and in males. The CRC detection rates in the first and 
second rounds were 2.5 and 1.6 per 1000 screened, 
respectively[38]. 
Croatia: The Croatian screening program was im-
plemented in 2007 for the population aged 50-74 years. 
They implemented the G-FOBT. Participation was low, 
reaching 19.9%. Positive tests were found in 6.9% 
cases, and of these, only 66% received a colonoscopy. 
CRC was identified in 472 patients (3.8%)[39].
Lithuania: The Lithuanian National Screening Pro-
gram began in 2009, for the population aged 50 to 
74 years. The FIT was applied. The participation rate 
for 3 years was 46% (271396). A positive FIT was 
observed in 19455 participants (7.2%). Of these, 
66.1% underwent a colonoscopy. High-grade neoplasia 
was detected in 3.9% of cases, and the rate of CRC 
was 3.1% among all colonoscopies. The rate of CRC 
detected with the program was 0.2%[40].
Slovenia: The Slovenian National Screening Program 
(SVIT program) started in 2009. This program 
performed a biennial FIT for the population aged 
50 to 69 years during 2014. The participation rate 
was 57.8% (53.2% men, 62.3% women). In this 
population, 6% had positive test results (7.6% men 
and 4.7% women). The colonoscopies detected 159 
(2.12%) patients with CRC and 1887 (25.16%) 
patients with advanced adenomas[41]. 
England: The English National Screening Program 
began in 2006 for the population aged 60 to 69 years. 
This program performed a biennial G-FOBT. The 
first round was completed in 2010. Of the 2 million 
invitations sent, 49.6% of men and 54.4% of women 
responded. The overall participation rate was 52%. 
Positive test results were found in 2% (2.5% men, 1.5% 
women). Among the colonoscopies performed (83%), 
CRC was detected in 10.1% (n = 1772; detection 
rates of 11.6% in men and 7.8% in women). High risk 
adenomas were detected in 9.8% (n = 1721; detection 
rates of 12.2% in men and 6.2% in women)[42]. 
Czech Republic: The Czech National Screening 
Program started in 2000 for individuals older than 50 
years. They applied a biennial G-FOBT. By 2009, the 
FIT was introduced. The coverage of CRC screening in 
2010 was 22.7%[43]. The results of the program from 
2001 to 2011 are shown in Table 3.
France: The French National screening program 
started in 2008 for the population aged 50-74 years. 
They applied the G-FOBT. The participation rate was 
34.3%. Positive test results were found in 2.8%. 
Of these, 88% underwent a colonoscopy. CRC was 
detected in 7.5% (detection was 9% in men and 5.8% 
in women). The advanced adenoma detection rate was 
4.9 per 1000 screened; the CRC detection rate was 
1.9‰[44]. 
CRC screening programs in the Americas
United States: Currently in the US, screening 
programs have been established on an opportunistic 
basis. The average-risk population (50-75 years) 
are encouraged to undergo screening at 50 years of 
age, and participants choose among several options. 
The available options are: (1) annual G-FOBT or FIT, 
according to the manufacturer’s recommendations 
for specimen collection; (2) multi-target stool DNA 
test every 3 years; (3) flexible sigmoidoscopy every 
5 years; (4) colonoscopy every 10 years; (5) double-
contrast barium enema every 5 years; or (6) CT 
colonography every 5 years. In about 90% of cases, 
colonoscopy is the preferred option[28].
On the other hand, screening program evaluations 
have been conducted in several regions of the country. 
For example, the Kaiser Permanente Northern and 
Southern California program conducted 4 screening 
rounds in a population of 50 to 70 years. They used 
the annual FIT (cut-off value 20 µg/g). They achieved 
a 48.2% participation rate in the first round. A positive 
2006 2007 2008 2009 2010 2011 Total
Examined patients (n) 272658 320317 352595 414300 521429 NA 1881299
Positivity rate   3.6%   3.3%   4.1%   5.0%   6.1% NA   4.6%
PPV for advanced adenoma  14.1% 13.5% 16.2% 16.6% 16.8% 16.7% 16.2%
PPV for CRC    6.3%   5.9%   6.0%   5.1%   4.5%   3.6%   4.8%
Navarro M et al . CRC population screening programs worldwide
CRC: Colorectal cancer; PPV: Positive predictive value.
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FIT result was found in 5% of participants and the 
PPVs were 51.5% for adenomas and 3.4% for CRC[45].
Canada: Canada organized a CRC screening pro-
gram for average-risk individuals, aged 50-74 years, 
from January 2009 to December 2011. Five pro-
vincial programs were included (British Columbia, 
Saskatchewan, Manitoba, Nova Scotia, and Prince 
Edward Island). The results of the first round showed 
very low participation rates (16.1%)[46]. The test 
positivity rate was 4.4% (4.8% with FIT and 3.7% 
with G-FOBT). Positive test results were more frequent 
in men (5.9%) than in women (3.4%), and the 
frequency increased with age: positive tests were 
found in 5.7% of the 70-74 age group and 3.4% of 
the 50-54 age group. Compliance with a follow-up 
colonoscopy was 80.5%. The detection rates were 
16.9 per 1000 screened for adenomas, and 1.8 per 
1000 screened for CRC. The PPVs for adenoma were 
35.9% with the G-FOBT and 50.6% with the FIT. The 
PPV for CRC was 4.4% in both tests.
Chile: In Chile, an organized screening program was 
launched between 2007 and 2009 in asymptomatic 
subjects, aged 50 years or older without risk factors. 
They applied the FIT test with a cutoff of 20 µg/g. 
The participation rate was 77%. Of 4938 participants, 
positive test results were found in 9.6%. Of these, a 
colonoscopy was performed in 58.6%. CRC detection 
rates were 2 per 1000 screenings[47].
CRC screening programs in the western pacific and east 
asia
The Asian Pacific Colorectal Cancer Working Group 
has recommended organized screening in regions 
with the highest CRC incidence (> 30 per 100000)[48]. 
The programs target average-risk individuals, aged 
50-75 years, and they preferably apply the FIT test. 
Several studies have investigated the barriers to 
CRC detection in different cultural and socio-political 
contexts in the Asia-Pacific region. These barriers 
included poor understanding of the characteristics of 
screening and testing, lack of financial support, and 
lack of health insurance[49]. Several countries in East 
Asia have ongoing organized screening programs, 
including Japan, Korea, China, Hong Kong, Taiwan, 
and Bangkok[50]. The results for several of these CRC 
Screening Programs are described below and in Table 4.
Japan: In Japan, a CRC screening program has 
been in place since 1992 for beneficiaries of health 
insurance, aged 40-69 years. The program applies the 
FIT. In 2013, participation rates were 41.4% in men 
and 34.5% in women[51]. 
South Korea: The South Korean National Screening 
Program was introduced in 2004. It targets the 
National Health Insurance population, aged over 50 
years. They employ an annual FIT (qualitative or 
quantitative). Participation increased from 10.5% in 
2004 to 21.1% in 2008 and to 25% in 2012[52]. In 
2008, the FIT positivity rate was 7.5% (8.8% in men 
and 6.4% in women). A colonoscopy was performed 
in 31.4% of those with positive test results. The CRC 
detection rate was 1.2%[53].
Taiwan: The Taiwanese National program began in 
2004. They performed biennial FITs in individuals aged 
50 to 69 years. In the first round, 1160895 individuals 
(21.4%) participated. The test positivity rate was 4%. 
Subsequent colonoscopies detected 4284 advanced 
adenomas (detection rate 4.6 per 1000) and 2304 
CRCs (detection rate 2.5 per 1000). The PPVs of FITs 
were 11.7% for advanced adenoma, and 6.1% for 
CRC[54].
Thailand: A Thai pilot screening program was 
implemented in 2011. The FIT was performed in the 
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Table 4  Results of American, Western Pacific and East Asian screening programs 
Country Canada California 
(United States)
South Korea Australia Thailand Taiwan Chile
ASRi 35.5 25 (United States) 45 38 12.4 NA 15
ASRm 10.8 9.2 (United States) 12 9 7.3 NA 8.6
Period 2009-2011 2008 2004-2008 2002-2004 2011-2012 2004-2009 2007-2009
Age range 50-74 50-70 50-75 55-74 50-65 50-69 > 50
Test G-FOBT/FIT FIT FIT FIT FIT FIT FIT
Participation, n (%) 104750 (16.1) 323349 (48.2) 984915 (21) 25840 (45.4) 80012 (62.9)  1160895 (21.4) 4938
M, n (%) 446590 (20.5) 57.8%    446290 (20.4)
F, n (%) 538325 (21.9) 67.8% 714605 (25)
Positive test, n (%) 4661 (4.4) 5% 73568 (7.5) 2308 (8.9) 873 (1.1) 4% 476 (9.6)
M, n (%) 5.9% 39233 (8.8) 1.2% 5%
F, n (%) 3.4% 34335 (6.4) 1.1% 3.4%
Colonoscopies performed 80.5% NA 23117 (31.4) 1265 (54.8) 627 (71.8) 80% 279 (58.6)
Advanced adenoma, n (%) NA NA NA 176 (13.9) 75 (12%) 4284 75 (16)
PPV Advanced adenoma NA NA NA NA NA NA NA
CRC, n (%) 86 1.2% 67 (5.3) 23 (3.7) 2304 13 (1.1)
PPV CRC 4.4% 3.4%
CRC Detection rate per 1000 1.8 NA NA 2.59 0.29 2.5 2
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population aged 50-65 years in Lampang Province. The 
participation rate (62.9%) was higher among women 
(67.8%) than men (57.8%). The test was positive 
in 1.1% (1.2% men, 1.0% women). Colonoscopy 
was performed in 72% of those with positive tests. 
Detection rates were 3.7% for CRC and 30.6% for 
adenomas[55].
Australia: An Australian pilot program was conducted 
from 2002 to 2006 with the biennial FIT in the 
population aged 55-74 years. The participation rate 
was 45.4% (women 47.4%, men 43.4%). Positive FIT 
results were found in 9% of participants. Colonoscopy 
was performed in 54.8% of the individuals with 
positive FITs. Adenomas were found in 19.8% (13.9% 
advanced) and CRC was found in 5.3%[56]. In 2006, 
The National Bowel Cancer Screening Program was 
initiated with a biennial FIT for the population aged 
55-65 years. The program will continue to expand until 
2020. The program aims to apply biennial screening to 
the entire population aged 50-74 years[4]. 
COMPARISON OF THE RESULTS OF 
SEVERAL CRC SCREENING PROGRAMS
Most European countries have implemented a national 
organized screening program. However, some countries 
have not, despite high CRC incidence and mortality 
rates, such as Slovakia. Likewise, most countries of 
Central America, South America, the Middle East, and 
Africa, do not have organized screening programs. 
In most cases, the lack of organized programs could 
be explained by limited resources, including the 
limited availability of colonoscopy facilities, and the 
type of organization of the Health Care System. Most 
organized screening programs use non-invasive tests 
(FIT or G-FOBT); in contrast, most opportunistic 
programs rely on endoscopy. Colonoscopy remains the 
most commonly used screening test in North America, 
but FIT screening programs are beginning to be 
implemented in some areas, such as California[45].
The efficacy of CRC screening is determined by the 
degree of participation and the diagnostic yield of the 
test. Studies have shown that FIT screening is superior 
to G-FOBT in both aspects[20,47]. The overall results 
showed that the highest participation rates were 
obtained in programs using FIT. In fact, in programs 
that used both tests (FIT and G-FOBT), participation 
rates increased after FIT was introduced, as observed 
in the Czech Republic[43].
FIT screening also produced more positive tests 
than G-FOBT screening. Therefore, the lowest rates 
of test positivity in Europe were obtained in England 
and France, where screening was performed with the 
G-FOBT[42,44]. As mentioned, in the Czech Republic 
program, after the G-FOBT was replaced with the 
FIT, the PPV for advanced adenoma increased, and 
the PPV for CRC decreased[43]. This result implied 
that, compared to the G-FOBT, the FIT had a higher 
sensitivity and PPV for advanced adenomas, but a 
lower PPV for CRC. 
Among all the programs reviewed, only Korea used 
a qualitative FIT. Studies worldwide using different 
Hb thresholds have shown that defining a positive 
FIT result with a cut-off value of 100 ng/mL Hb (20 
µg/g) provided high sensitivity, specificity, and PPV for 
detecting neoplasia[49,53,54]. Other studies reported a 
decline in specificity with cut-off values below 100 ng/mL 
Hb[5,45,46,48,53]. According to this information, a cutoff 
value between 75 and 100 ng/mL Hb might represent 
an optimum in most European populations, depending 
on the resources and availability of colonoscopy.
Some countries had to modify the cut-off value 
to align the need for colonoscopies with the limited 
capacity of endoscopic resources. For example, in the 
Netherlands, which had the highest rates of positivity 
among all international and European programs, the 
cutoff value was raised from 88 to 275 ng/mL Hb (15 
µg/g to 47 µg/g) at the beginning of their program[35]. 
In addition, the Netherlands had the highest CRC 
detection rate in Europe; the detection rates were 
double those of several European and other countries. 
The program in Ireland also had a high percentage 
of positive tests (10%). In comparison, with the 
same cut-off value, Italy had almost half (5.8%) the 
proportion of positive tests. This suggested that there 
might be a relatively high incidence of adenomas in 
Ireland, and that lower cut-off values would be very 
difficult to manage with the current availability of 
colonoscopy resources in the country.
Another problem to consider is the low acceptance 
of colonoscopy in some countries. In South Korea, only 
31.4% of individuals with a positive FIT had undergone 
a colonoscopy after. This reluctance could result in low 
detection rates[53]. In other European countries, like 
Croatia, Lithuania, and The Netherlands, the proportion 
of colonoscopies among individuals with positive test 
results did not exceed 75%[35,39,40]. 
Participation rates in the screening programs were 
higher among women than men. This difference 
probably occurred because women had a greater 
awareness of preventive programs; in particular, 
women were likely to have had experience in breast 
and cervix screening. In addition, positive FIT rates 
were significantly higher in men than in women (except 
in Ireland and Thailand, where rates were similar 
between the sexes). The CRC detection rates were 
also higher in men than in women; in some programs, 
detection rates in men were double the rates in 
women. Special efforts should be made in all screening 
programs to increase both the overall participation and 
male participation rates. 
The lowest participation rates were found in 
Canada, possibly because the data were published 
recently after the programs had been started.
In general, participation rates in the different 
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programs currently exceed the acceptable minimum 
of 45%, but they have not reached the desired 
target (> 65%). Screening programs must employ 
specific strategies to attract the target population 
and encourage participation in screening programs. 
A better understanding of the barriers and facilitators 
to participation is needed to design strategies that 
promote equity of access. It is important to monitor, 
record, and evaluate the minimum indicators and 
requirements of CRC Population Screening Programs, 
to ensure they meet the standards of the European 
Quality Control Guide.
CONCLUSION
This review highlighted the large variations in CRC 
incidence and mortality around the world. Some regions 
with high CRC rates do not have screening programs, 
and other regions, like Europe, have widespread 
organized screening programs. Additionally, participation 
rates vary greatly between programs around the world. 
The highest rates were found in the Netherlands and 
the lowest were found in Canada. The most common 
test used as a screening tool in organized screening 
programs was the fecal occult blood test. In countries 
with screening programs that arose opportunistically, 
colonoscopy was most commonly used for screening. 
Between the two types of fecal occult blood tests, the 
most commonly used test was the FIT. Use of the 
FIT has increased participation rates, because it is 
user friendly; a single sample suffices, and no dietary 
restrictions are imposed prior to the test. Because the 
FIT is more sensitive than the G-FOBT, the number of 
false positives and the demand for invasive tests has 
increased. Consequently, the cut-off value of the test 
must be adapted to each region, taking into account 
the availability of endoscopic resources. The FIT also 
exhibited superior detection of advanced adenomas 
compared to the G-FOBT. This feature promotes 
treatment in early stages and prevents the formation 
of cancer. Participation rates were higher among 
women, possibly due to their increased awareness of 
the importance of other screening programs, such as 
breast cancer screening. Positive test results and CRC 
detection rates were higher in men than in women; 
therefore, men’s awareness should be increased to 
encourage participation in screening programs.
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